NASDAQ : AMLX
Amylyx Pharmaceuticals, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 28.86 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.62B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.62B |
| Enterprise Value | 3.38B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 125.51M |
| Shares Outstanding | 125.51M |
| Shares Change (YoY) | +36.47% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 6.05% |
| Owned by Institutions (%) | 85.40% |
| Float | 109.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 13.44 |
| P/TBV Ratio | 15.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.12 |
| Quick Ratio | 11.88 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -74.73% |
| Return on Assets (ROA) | -44.13% |
| Return on Invested Capital (ROIC) | -48.45% |
| Return on Capital Employed (ROCE) | -66.60% |
| Weighted Average Cost of Capital (WACC) | 3.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.12M |
| Employee Count | 136 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 46,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.09 |
| 52-Week Price Change | +107.78% |
| 50-Day Moving Average | 30.89 |
| 200-Day Moving Average | 20.08 |
| Relative Strength Index (RSI) | 51.89 |
| Average Volume (20 Days) | 1,313,896 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13.25M |
| Short Previous Month | 12.67M |
| Short % of Shares Out | 10.56% |
| Short % of Float | 12.09% |
| Short Ratio (days to cover) | 9.49 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -92.45M |
| Operating Income | -162.10M |
| Pretax Income | -152.05M |
| Net Income | -152.09M |
| EBITDA | -161.73M |
| EBIT | -162.10M |
| Earnings Per Share (EPS) | -$1.43 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 250.76M |
| Total Debt | 5.26M |
| Net Cash | 245.51M |
| Net Cash Per Share | $1.96 |
| Equity (Book Value) | 239.17M |
| Book Value Per Share | 2.15 |
| Working Capital | 235.19M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -126.58M |
| Capital Expenditures | -140,000 |
| Depreciation & Amortization | 369,000 |
| Net Borrowing | 190.74M |
| Free Cash Flow | -126.72M |
| FCF Per Share | -$1.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.47% |
| Shareholder Yield | -36.47% |
| Earnings Yield | -4.96% |
| FCF Yield | -3.50% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $42.64 |
| Price Target Difference | 47.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |